ZYMBOSI Trademark

Trademark Overview


On Monday, January 14, 2019, a trademark application was filed for ZYMBOSI with the United States Patent and Trademark Office. The USPTO has given the ZYMBOSI trademark a serial number of 88260967. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 17, 2022. This trademark is owned by Eli Lilly and Company. The ZYMBOSI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
zymbosi

General Information


Serial Number88260967
Word MarkZYMBOSI
Filing DateMonday, January 14, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 17, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 16, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 5, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Tuesday, January 18, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 17, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, May 19, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 17, 2021EXTENSION 4 GRANTED
Monday, May 17, 2021EXTENSION 4 FILED
Monday, May 17, 2021TEAS EXTENSION RECEIVED
Friday, December 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 3, 2020EXTENSION 3 GRANTED
Tuesday, November 17, 2020EXTENSION 3 FILED
Thursday, December 3, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, November 17, 2020TEAS EXTENSION RECEIVED
Friday, May 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 20, 2020EXTENSION 2 GRANTED
Wednesday, May 20, 2020EXTENSION 2 FILED
Wednesday, May 20, 2020TEAS EXTENSION RECEIVED
Wednesday, November 20, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 18, 2019EXTENSION 1 GRANTED
Monday, November 18, 2019EXTENSION 1 FILED
Monday, November 18, 2019TEAS EXTENSION RECEIVED
Tuesday, June 11, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 16, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 16, 2019PUBLISHED FOR OPPOSITION
Wednesday, March 27, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, March 9, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, March 9, 2019ASSIGNED TO EXAMINER
Tuesday, February 5, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, January 17, 2019NEW APPLICATION ENTERED IN TRAM